Posted by Michael Wonder on 06 Dec 2022
Pfizer and BioNTech submit application to US FDA for emergency use authorisation of Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine in children under 5 years
5 December 2022 - Pfizer andBioNTech today announced that the companies have submitted an application to the US FDA for emergency use authorisation of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3 µg dose in the three dose primary series for children 6 months through 4 years of age.
With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalisation.
